Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3509168 | 1.00 | TTR (0.43) | TTRALBMEN1KMT2AHTT | |
| SCHEMBL2011602 | 0.82 | TTR (0.40) | TTRALBMEN1KMT2AHTT | |
| SCHEMBL200313 | 0.82 | TTR (0.52) | TTRALBMEN1KMT2AHTT | |
| SCHEMBL504640 | 0.82 | TTR (0.52) | TTRALBMEN1KMT2AHTT | |
| SCHEMBL3182180 | 0.82 | TTR (0.40) | TTRALBMEN1KMT2AHTT | |
| Hydrochloric Acid SCHEMBL9495207 | 0.79 | TTR (0.39) | TTRALBMEN1KMT2AHTT | |
| Isonicotinonitrile SCHEMBL6397797 | 0.76 | TSHR (0.38) | MEN1KMT2AHTTMAPTMAOA | |
| SCHEMBL16950941 | 0.73 | TTR (0.44) | TTRALBMEN1KMT2AHTT | |
| SCHEMBL1979138 | 0.73 | TTR (0.40) | TTRALBMEN1KMT2AMAOA | |
| SCHEMBL219619 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | ONCODESIGN S.A. (FR) | 2026-05-19 | — | — | US | disclosed |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2026-05-07 | — | — | US | disclosed |
| WO-2025215121-A1 | HEDGEHOG ACYLTRANSFERASE INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-10-16 | — | — | WO | disclosed |
| EP-4178576-A1 | DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORS | Emergent Product Development Gaithersburg Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | TTR 3984/4885ALB 4498/4885MEN1 1403/4885 |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | RIPK1, RIPK2, RIPK3 | TTR 4034/4885ALB 4771/4885MEN1 3378/4885 |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK2, RIPK1, RIPK3 | TTR 4274/4885ALB 3865/4885MEN1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.